← Leaderboards
Yi-Fen Lee
University Of Rochester
$4,026,830
Attributed
$4,026,830
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $449.3K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,026,830 · 3
By mechanism
R01$4,026,830 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Catherine Ovitt$9,674,992
- Danielle S. Benoit$10,277,461
- Lisa A. Delouise$6,904,175
- Yuhchyau Chen$4,833,616
- Jomy Jo Varghese$192,160
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMediatingGenesCellsAffectCancer PatientMolecularPathway InteractionsPreventMolecular ProfilingNovel DiagnosticsKnock-DownCell ProliferationLeadSignal TransductionTumorBehaviorElderlyDisease ProgressionDiagnosisCancer CellMalignant NeoplasmsBiologicalTumorigenesis
Grant awards (12)
Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapy$431,650
R01 · FY2025 · CA · contact PI
Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapy$449,295
R01 · FY2024 · CA · contact PI
Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression$376,236
R01 · FY2018 · CA · contact PI
Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression$376,236
R01 · FY2017 · CA · contact PI
Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression$365,944
R01 · FY2016 · CA · contact PI
Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression$346,833
R01 · FY2015 · CA · contact PI
Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression$346,833
R01 · FY2014 · CA · contact PI
TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis$261,900
R01 · FY2012 · CA · contact PI
TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis$261,900
R01 · FY2011 · CA · contact PI
TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis$270,001
R01 · FY2010 · CA · contact PI
TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis$270,001
R01 · FY2009 · CA · contact PI
TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis$270,001
R01 · FY2008 · CA · contact PI